Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:lu ;pers:(Dillner Joakim)"

Sökning: LAR1:lu > Dillner Joakim

  • Resultat 1-10 av 144
Sortera/gruppera träfflistan
  • Andersson, Kristin, et al. (författare)
  • Prospective Study of Human Papillomavirus Seropositivity and Risk of Nonmelanoma Skin Cancer
  • 2012
  • Ingår i: American Journal of Epidemiology. - Oxford University Press. - 1476-6256 .- 0002-9262. ; 175:7, s. 685-695
  • Tidskriftsartikel (refereegranskat)abstract
    • Cutaneous human papillomaviruses (HPVs) have been associated with squamous cell carcinoma (SCC) in case-control studies, but there are limited data from prospective studies assessing whether virus exposure predicts risk of future cancer development. Two major biobanks, the Southern Sweden Microbiology Biobank (1971-2003) and the Janus Biobank (1973-2003) in Norway, containing samples from 850,000 donors, were searched for incident skin cancer for up to 30 years using registry linkages. Altogether, 2,623 donors with samples taken before diagnosis of SCC or basal cell carcinoma (BCC) of the skin were identified. Prediagnostic samples and samples from 2,623 matched controls were tested for antibodies against 33 types of HPV. Baseline seropositivity to HPV types in genus beta species 2 was associated with SCC risk (odds ratio = 1.3, 95% confidence interval: 1.1, 1.7); this was also the case for samples taken more than 18 years before diagnosis (odds ratio = 1.8, 95% confidence interval: 1.1, 2.8). Type-specific persistent seropositivity entailed elevated point estimates for SCC risk for 29 HPV types and decreased point estimates for only 3 types. After multiple hypothesis adjustment, HPV 76 was significantly associated with SCC risk and HPV 9 with BCC risk. In summary, seropositivity for certain HPV types was associated with an increased risk for future development of SCC and BCC.
  • Andersson, Kristin, et al. (författare)
  • Seroreactivity to Cutaneous Human Papillomaviruses among Patients with Nonmelanoma Skin Cancer or Benign Skin Lesions.
  • 2008
  • Ingår i: Cancer Epidemiology Biomarkers & Prevention. - 1055-9965. ; 17:1, s. 189-195
  • Tidskriftsartikel (refereegranskat)abstract
    • Cutaneous human papillomaviruses (HPV) are common in nonmelanoma skin cancers, benign skin lesions, and healthy skin. Increased seroprevalences for cutaneous HPV among nonmelanoma skin cancer patients have been described. To determine whether antibodies to cutaneous HPV are related to presence of the virus and/or to skin disease, we collected serum and biopsies from both lesions and healthy skin from 434 nonimmunosuppressed patients (72 squamous cell carcinomas, 160 basal cell carcinomas, 81 actinic keratoses, and 121 benign lesions). Biopsies were analyzed for HPV DNA by PCR, cloning, and sequencing. Serum antibodies to the major capsid protein L1 of HPV 1, 5, 6, 8, 9, 10, 15, 16, 20, 24, 32, 36, 38, and 57 as well as to the oncoproteins E6 and E7 of HPV 8 and 38 were detected using a multiplexed fluorescent bead-based assay. Type-specific seroprevalence among patients with the same type of HPV DNA (sensitivity of serology) varied from 0% to at most 28%. Presence of HPV DNA and antibodies to the same HPV type was not significantly correlated. However, seropositivity to any HPV type was significantly more common among patients positive for HPV DNA of any HPV type (odds ratio, 1.90; 95% confidence interval, 1.55-2.34). Seroprevalences were similar among the different patient groups but was, for most HPV types, somewhat higher among squamous cell carcinoma patients than among basal cell carcinoma patients (P < 0.01). In conclusion, additional studies are required to clarify the biological meaning of seropositivity as a marker of cutaneous HPV infection and skin disease. (Cancer Epidemiol Biomarkers Prev 2008;17(1):189-95).
  • Andersson, Kristin, et al. (författare)
  • The interface of population-based cancer registries and biobanks in etiological and clinical research : current and future perspectives
  • 2010
  • Ingår i: Acta Oncologica. - 0284-186X. ; 49:8, s. 1227-1234
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The availability of quality assured, population-based cancer registries and biobanks with high quality samples makes it possible to conduct research on large samples sets with long follow-up within a reasonable time frame. Defined quality for both cancer registries and biobanks is essential for enabling high quality biobank-based research. Recent networking projects have brought these infrastructures together to promote the combined use of cancer registries and biobanks in cancer research.MATERIALS AND METHODS: In this report we review the current status and future perspectives of cancer registries and biobanks and how the interface between them should be developed to optimally further cancer research.RESULTS AND DISCUSSION: Major conclusions for future improvements are that the research exploiting cancer registries and biobanks, and the research that is building and optimising the infrastructure, should evolve together for maximally relevant progress. Population-based and sustainable biobanks that continuously and consecutively store all samples ("Biological registries") under strict quality control are needed. There is also a need for increased education, information and visibility of the interdisciplinary sciences required for optimal exploitation of these resources.
  • Andrae, Bengt, et al. (författare)
  • Screening-preventable cervical cancer risks evidence from a nationwide audit in Sweden.
  • 2008
  • Ingår i: J Natl Cancer Inst. - 1460-2105. ; 100:9, s. 622-9
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The effectiveness of cervical cancer screening programs differs widely in different populations. The reasons for these differences are unclear. Routine and comprehensive audits have been proposed as an ethically required component of screening. We performed a nationwide audit of the effectiveness of the Swedish cervical cancer screening program.Methods: We identified all invasive cervical cancer cases that were diagnosed in Sweden from January 1, 1999, through December 31, 2001, and had been reported to the Swedish Cancer Registry (n = 1230 cases). We verified the diagnoses by histopathologic rereview and matched each case subject to five (population-based) age-matched control subjects who were identified from the National Population Register. The Pap smear screening histories for case and control subjects were reviewed for a 6-year period using the National Cervical Cancer Screening Register, which contains data on essentially all relevant cytological and histological diagnoses in Sweden. Odds ratios (ORs), and their 95% confidence intervals (CIs), of cervical cancer according to screening history were calculated in conditional logistic regression models. All statistical tests were two-sided.Results: Women who had not had a Pap smear within the recommended screening interval had higher risk of cervical cancer than women who had been screened (OR = 2.52, 95% CI = 2.19 to 2.91). This risk was similarly increased for all age groups (Phomogeneity = .96). The risk for nonsquamous cell cervical cancers (OR = 1.59, 95% CI = 1.20 to 2.11) was also increased. Women who had not had a Pap smear within the recommended screening interval had a particularly high risk of advanced cancers (OR = 4.82, 95% CI = 3.61 to 6.44). Among women who had been screened within the recommended interval, those with abnormal Pap smears had a higher risk of cervical cancer than those with normal smears (OR = 7.55, 95% CI = 5.88 to 9.69) and constituted 11.5% of all women with cervical cancer.Conclusions: Nonadherence to screening intervals was the major reason for cervical cancer morbidity. The screening program was equally effective for women of all ages and was also effective against nonsquamous cancers.
  • Anttila, T, et al. (författare)
  • Chlamydial antibodies and risk of prostate cancer
  • 2005
  • Ingår i: Cancer Epidemiology Biomarkers & Prevention. - American Association for Cancer Research. - 1055-9965. ; 14:2, s. 385-389
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: We assessed the risk of prostate cancer by exposure to Chlamydia trachomatis. Method: Seven hundred thirty eight cases of prostate cancer and 2,271 matched controls were identified from three serum sample banks in Finland, Norway, and Sweden by linkage to the population based cancer registries. Results: A statistically significant inverse association (odds ratio, 0.69; 95% confidence interval, 0.51-0.94) was found. It was consistent by different serotypes and there was a consistent dose-response relationship. Conclusion: C. trachomatis infection is not likely to increase the risk of prostate cancer. Whether the inverse relationship is true or due to difficulties in measuring the true exposure in prostatic tissue by serology, confounders or other sources of error remain open.
  • Appleby, P, et al. (författare)
  • Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16 573 women with cervical cancer and 35 509 women without cervical cancer from 24 epidemiological studies
  • 2007
  • Ingår i: The Lancet. - Elsevier. - 1474-547X .- 0140-6736. ; 370:9599, s. 1609-1621
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Combined oral contraceptives are classified by the International Agency for Research on Cancer as a cause of cervical cancer. As the incidence of cervical cancer increases with age, the public-health implications of this association depend largely on the persistence of effects long after use of oral contraceptives has ceased. Information from 24 studies worldwide is pooled here to investigate the association between cervical carcinoma and pattern of oral contraceptive use. Methods Individual data for 16 573 women with cervical cancer and 35 509 without cervical cancer were reanalysed centrally. Relative risks of cervical cancer were estimated by conditional logistic regression, stratifying by study, age, number of sexual partners, age at first intercourse, parity, smoking, and screening. Findings Among current users of oral contraceptives the risk of invasive cervical cancer increased with increasing duration of use (relative risk for 5 or more years' use versus never use, 1-90 [95% Cl 1-69-2-13]). The risk declined after use ceased, and by 10 or more years had returned to that of never users. A similar pattern of risk was seen both for invasive and in-situ cancer, and in women who tested positive for high-risk human papillornavirus. Relative risk did not vary substantially between women with different characteristics. Interpretation The relative risk of cervical cancer is increased in current users of oral contraceptives and declines after use ceases. 10 years' use of oral contraceptives from around age 20 to 30 years is estimated to increase the cumulative incidence of invasive cervical cancer by age 50 from 7.3 to 8.3 per 1000 in less developed countries and from 3.8 to 4.5 per 1000 in more developed countries.
  • Arbyn, Marc, et al. (författare)
  • Cervical cytology biobanking in Europe
  • 2010
  • Ingår i: International Journal of Biological Markers. - Wichtig Editore. - 1724-6008 .- 0393-6155. ; 25:3, s. 117-125
  • Tidskriftsartikel (refereegranskat)abstract
    • A cervical cytology biobank (CCB) is an extension of current cytopathology laboratory practice consisting in the systematic storage of Pap smears or liquid-based cytology samples from women participating in cervical cancer screening with the explicit purpose to facilitate future scientific research and quality audit of preventive services. A CCB should use an internationally agreed uniform cytology terminology, be integrated in a national or regional screening registry, and be linked to other registries (histology, cancer, vaccination). Legal and ethical principles concerning personal integrity and data safety must be respected strictly. Biobank-based studies require approval of ethical review boards. A CCB is an almost inexhaustible resource for fundamental and applied biological research. In particular, it can contribute to answering questions on the natural history of HPV infection and HPV-induced lesions and cancers, screening effectiveness, exploration of new biomarkers, and surveillance of the short- and long-term effects of the introduction of HPV vaccination. To understand the limitations of CCB, more studies are needed on the quality of samples in relation to sample type, storage procedures, and duration of storage.
  • Arbyn, M, et al. (författare)
  • Methods for screening and diagnosis
  • 2007
  • Ingår i: 2nd edition of the EU Guidelines for cervical cancer screening. - European Commission. - 978-92-79-07698-5 ; s. 69-141
  • Bokkapitel (övrigt vetenskapligt)
  • Arbyn, Marc, et al. (författare)
  • Review of current knowledge on HPV vaccination: An Appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
  • 2007
  • Ingår i: Journal of Clinical Virology. - Elsevier. - 1386-6532 .- 1873-5967. ; 38:3, s. 189-197
  • Forskningsöversikt (refereegranskat)abstract
    • The recognition of a strong etiological relationship between infection with high-risk human papillomavirusses and cervical cancer has prompted research to develop and evaluate prophylactic and therapeutic vaccines. One prophylactic quadrivalent vaccine using L1 virus-like particles (VLP) of HPV 6, 11, 16 and 18 is available on the European market since the end of 2006 and it is expected that a second bivalent vaccine containing VLPs of HPV 16 and HPV 18 will become available in 2007. Each year, HPV 16 and HPV 18 cause approximately 43,000 cases of cervical cancer in the European continent. Results from the phase-IIb and III trials published thus far indicate that the L1 VLP HPV vaccine is safe and well-tolerated. It offers HPV-naive women a very high level of protection against HPV persistent infection and cervical intra-epithelial lesions associated with the types included in the vaccine. HPV vaccination should be offered to girls before onset of sexual activity. While prophylactic vaccination is likely to provide important future health gains, cervical screening will need to be continued for the whole generation of women that is already infected with the HPV types included in the vaccine. Phase IV studies are needed to demonstrate protection against cervical cancer and to verify duration of protection, occurrence of replacement by non-vaccine types and to define future policies for screening of vaccinated cohorts. The European Guidelines on Quality Assurance for Cervical Cancer Screening provides guidance for secondary prevention by detection and management of precursors lesions of the cervix. The purpose of the appendix on vaccination is to present Current knowledge. Developing guidelines for future use of HPV vaccines in Europe, is the object of a new grant offered by the European Commission. (C) 2006 Elsevier B.V. All rights reserved.
  • Arbyn, Marc, et al. (författare)
  • Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate
  • 2009
  • Ingår i: Journal of Cellular and Molecular Medicine. - Wiley-Blackwell Publishing. - 1582-1838 .- 1582-4934. ; 13:4, s. 648-659
  • Forskningsöversikt (refereegranskat)abstract
    • Introduction Methods Results Discussion Conclusion Consistent evidence underlines the utility of human papillomavirus (HPV) DNA testing in the management of women with equivocal cervical cytological abnormalities, but not in case of low-grade lesions. We performed a meta-analysis including studies where the high-risk probe of the Hybrid Capture-II is used to triage these two cytological categories. The triage test-positivity rate reflects the colposcopy referral workload.Data were pooled on the HPV test positivity rate in women with atypical squamous cells of undetermined significance (ASCUS/ASC-US) or low-grade squamous intraepithelial lesions (LSIL), derived from different cytological classification systems. The meta-analysis was restricted to studies, published between 1991 and 2007. A random-effect model was applied for meta-analytical pooling and the influence of covariates on the HPV positivity rate was analyzed by meta-regression. The variation by age was assessed within individual studies since age strata were not defined uniformly. On an average, 43% (95% CI: 40-46%) of women with ASCUS/ASC-US were high-risk HPV positive (range 23-74%). In women with LSIL, the pooled positivity rate was 76% (95% CI: 71-81%; range 55-89%). In spite of considerable inter-study heterogeneity, the difference in HPV positivity between the two triage groups was large and highly significant: 32% (95% CI: 27-38%). HPV rates dropped tremendously as age and cutoffs of test positivity increased. Other factors (cytological classification system, country, continent, collection method and year of publication) had no statistically significant impact, except in LSIL triage where HPV positivity was significantly lower in European compared to American studies. Women with LSIL, especially younger women, have high HPV positivity rates suggesting limited utility of reflex HPV triaging these cases. Research is needed to identify more specific methods to triage women with low-grade squamous cervical lesions.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 144
fritt online (45)
Typ av publikation
tidskriftsartikel (126)
forskningsöversikt (7)
annan publikation (5)
bokkapitel (5)
konferensbidrag (1)
Typ av innehåll
refereegranskat (137)
övrigt vetenskapligt (7)
Lehtinen, Matti (27)
Forslund, Ola (22)
Koskela, Pentti (16)
Paavonen, Jorma (12)
Ekström, Johanna, (10)
visa fler...
Luostarinen, Tapio (10)
Andersson, Kristin, (9)
Pukkala, Eero (9)
Bosch, F. Xavier (9)
Ekstrom, J (8)
Lehtinen, M (7)
Hallmans, Göran (7)
Naucler, Pontus, (7)
Pawlita, Michael, (7)
Koutsky, Laura A. (7)
Ault, Kevin A. (7)
Ferris, Daron G. (7)
Bzhalava, Davit (7)
Sparén, Pär, (6)
de Villiers, Ethel-M ... (6)
Dillner, Lena (6)
Silins, Ilvars (6)
Hakama, Matti (6)
Brown, Darron R. (6)
Kjaer, Susanne K. (6)
Sigurdsson, Kristjan (6)
Hernandez-Avila, Mau ... (6)
Perez, Gonzalo (6)
Tay, Eng Hseon (6)
Majewski, Slawomir (6)
Munoz, Nubia (6)
Myers, Evan R. (6)
Villa, Luisa L. (6)
Taddeo, Frank J. (6)
Tadesse, Amha (6)
Hesley, Teresa M. (6)
Barr, Eliav (6)
Faust, Helena, (6)
Ogmundsdottir, Helga ... (6)
Jellum, Egil (6)
Thoresen, Steinar (6)
Lundstig, Annika (5)
Castellsague, Xavier ... (5)
Waterboer, Tim, (5)
Arbyn, Marc (5)
Arbyn, M (5)
Persson, Kenneth (5)
Munoz, N (5)
Wheeler, Cosette M. (5)
visa färre...
Lunds universitet (144)
Umeå universitet (20)
Uppsala universitet (6)
Göteborgs universitet (5)
Linköpings universitet (4)
visa fler...
Stockholms universitet (1)
visa färre...
Engelska (136)
Svenska (8)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (142)
Naturvetenskap (4)


pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy